All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, February 1, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

India looks to cut reliance on China for APIs

April 6, 2020
By T.V. Padma
No Comments
NEW DELHI - In a bid to limit what is seen as excessive dependence on active pharmaceutical ingredients (APIs) from China, the Indian government has announced a $394 million scheme to promote the development of three bulk drug parks.
Read More
GM-CSF

Izana’s namilumab joins testing for COVID-19 arsenal as data point to GM-CSF as target for severe disease

April 6, 2020
By Nuala Moran
No Comments
LONDON – Izana Bioscience Ltd. has become the third company to supply an anti-GM-CSF antibody for compassionate use against COVID-19, announcing namilumab, currently in phase IIb testing in the treatment of rheumatoid arthritis and ankylosing spondylitis, will be used to treat 20 patients with severe respiratory symptoms.
Read More

Ansun Biopharma reveals positive results for novel COVID-19 candidate

April 6, 2020
By David Ho
No Comments
HONG KONG – Another promising candidate has emerged in the race to find a treatment for the COVID-19 coronavirus. San Diego-based Ansun Biopharma Inc. released positive results from a four-patient study of its DAS-181 candidate, which is being developed for the treatment of severe COVID-19 infection. 
Read More

Week in review for March 30-April 3, 2020: Coronavirus pandemic could shorten cash runways, derail clinical trials

April 6, 2020
By Peter Winter
No Comments
A quick look back at top stories.
Read More

Regulatory actions for April 6, 2020

April 6, 2020
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acceleron, BMS, Daiichi, Eisai, GW, Histogen, Hope, Mallinckrodt, Mateon, Mesoblast, Novo Nordisk, Takeda, Tetra, Tracon.
Read More

Other news to note for April 6, 2020

April 6, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Aim Immunotech, Akers, Alnylam, Assembly, Aurobindo, Biobridge Global, Bioardis, Evotec, Dicerna, Glaxosmithkline, Innovation, Intelgenx, Kalos, La Jolla, Mateon, Medincell, Oncology, Oncosec, Onxeo, Pharmabcine, Premas, Protokinetix, Qu, Redhill, Samsung Biologics, Shenogen, Sosei Heptares, Takeda, Vir, Xbiotech.
Read More

In the clinic for April 6, 2020

April 6, 2020
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aeterna Zentaris, American Brivision, Auris, Axsome, Bryn Pharma, Catalyst, Compugen, Cytodyn, Immunomedics, Incyte, Inovio, Janssen, Menlo, Millendo, Oxthera, Sun Biopharma, Windtree, Yiviva.
Read More

Regulatory front for April 6, 2020

April 6, 2020
No Comments
The latest global regulatory news, changes and updates affecting biopharma, including: Gilead.
Read More
Canadian flag

Ottawa recruits Canadian equipment makers in CA$2B COVID-19 battle

April 3, 2020
By David Godkin
No Comments
TORONTO – Canadian Prime Minister Justin Trudeau has yet to rule out following U.S. President Donald Trump’s lead by invoking his nation's wartime Defense Procurement Act compelling manufacturers to begin making ventilators to combat COVID-19. For now, Ottawa has signed contracts or letters of intent with eight equipment makers.
Read More
4-3-dunwoody-3d-shields.png

3D printing community rallies to meet hospitals’ needs in pandemic

April 3, 2020
By Meg Bryant
No Comments
As health care workers face critical shortages of personal protective equipment (PPE) to deal with the COVID-19 crisis, 3D printing companies, medical device manufacturers and other organizations are stepping up to produce face shields, ventilators and other needed supplies. For its part, Rehovot, Israel-based Stratasys Ltd. has assembled a coalition of more than 150 companies and universities to produce 3D-printed visors and clear plastic face shields. The coalition aims to produce up to 16,000 face shields per week by the end of next week.
Read More
Previous 1 2 … 438 439 440 441 442 443 444 445 446 … 495 496 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 31, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 31, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • Stem-cells2.png

    J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

    BioWorld
    After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing